A new vaccine provides hope for treating and even preventing the highly contagious and difficult-to-treat Clostridioides difficile infection, more commonly known as C. difficile or C. diff. In animal models, this first mRNA-LNP C. difficile vaccine was found to protect against C. difficile first-time infections and relapsing infections by inducing a robust immune response, promote clearance of existing C. diff bacteria from the gut, and even overcome deficits in host immunity to protect animals after infection, according to researchers at the Perelman School of Medicine at the University of Pennsylvania and Children’s Hospital of Philadelphia. The results, published in the journal Science, will pave the way for clinical trials of the vaccine.
Yep! The mRNA vaccine project started in the 1980’s and to provide an elaborate use case, they designed it to be a “blank check”. Meaning whatever disease, toxin, allergy, autoimmune disorder, or cancer researchers want to vaccinate against is likely possible.
So you could theoretically even make some ultra custom antibiotic that kills C.diff specifically. 😅
Well, vaccines are very different than antibiotics. While there was the first new antibiotic made in ages earlier this year that’s highly selective for specific bacteria, it only works against gram-negative bacterial cells. C. diff is gram-positive and has been an issue for a long time. It’s notorious for it’s recurrence rate as it’s great at surviving conditions which kill most bacteria. It infects 500,000 people each year, with 20%+ of them being a reoccurring infection. Since new antibiotics are very tough to engineer, a vaccine makes way more sense and it will provide treatment for half a million people annually moving forward!